Tactile Medical Third Quarter 2026 Earnings Conference Call - TACTILE SYSTEMS TECHNOLOGY INC

Financial Performance:

• Q3 2026 total revenue reached $91.9 million, a 7.1% year-over-year increase.
• Lymphedema revenue grew 13% YoY to $81.8 million; Airway clearance revenue declined 25% YoY to $10 million due to DME inventory transitions.
• Gross margin expanded 90 basis points YoY to 76.7%, marking the 12th consecutive quarter of expansion.
• Adjusted EBITDA was $14.3 million, driven by margin expansion despite a 12.7% increase in operating expenses to $60.9 million.
• Net income was $7.2 million ($0.31 per share), down from $8.2 million in the prior year period.
• Year-to-date revenue increased 12% to $252.8 million; Adjusted EBITDA grew approximately 35% to $29.5 million.
• Ended Q3 with $75.1 million in cash and no debt; generated $12 million in operating cash flow, funding $6.2 million in share repurchases.
• Approximately $12.5 million remains available under the $25 million share repurchase program.

Guidance and Future Outlook:

• Maintained full-year 2026 revenue guidance of $360 million to $366 million (low single-digit to low double-digit growth).
• Raised full-year 2026 adjusted EBITDA guidance to $50–$52 million, up from previous expectations, reflecting strong lymphedema growth.
• Updated full-year airway clearance outlook to a mid-to-high single-digit decline, citing slower DME inventory clearance than anticipated.
• Expects sequential improvement in airway clearance revenue in Q4, though year-over-year growth will moderate due to a strong 2025 comparison.
• Projected full-year 2026 gross margin of approximately 76.5%; operating expenses expected to grow 10–12%.
• Long-term outlook remains confident on low double-digit lymphedema growth, supported by the launch of FlexiTouch Pro (targeted H2 2027) and Myosleeve (U.S. launch pending).
• No specific 2027 revenue guidance provided, but management expects continued durable growth and operating leverage.

Business Segments and Product Lines:

• Lymphedema: Core growth engine; Medicare revenue grew 11% and commercial revenue grew 17% in Q3. Strategic priorities include expanding access via the Lymphatec 3D scanner and converting referrals to shipments.
• Airway Clearance: Revenue decline attributed to one-time inventory transition for the next-generation AfloVest; no change in underlying patient demand.
• New Products & R&D: Filed for FDA 510K clearance for FlexiTouch Pro (enhanced pneumatic compression) targeting H2 2027 launch; U.S. commercialization of Myosleeve via Elastomed partnership anticipated post-VA pilot in late Q4.
• Lymphatec 3D Scanner: Received expanded FDA indication for circumference and volume measurement; Category 3 CPT code application pending final review in February 2027.
• Operational Changes: Appointed Steve Kiewit as Chief Operating Officer to lead order operations and patient services, aiming to streamline the referral-to-shipment process.

Market and Competitive Landscape:

• Lymphedema market remains significantly underpenetrated with an estimated 20 million undiagnosed U.S. patients; company maintains leadership in basic and advanced pneumatic compression.
• Market share stability evidenced by 19% YoY increase in clinic visits and >10% growth in referring clinics year-to-date.
• Commercial payers are beginning to remove "experimental/investigational" designations for FlexiTouch therapy related to head and neck cancer, following clinical trial data.
• AfloVest remains the only untethered, connected, and lightest airway clearance vest; product feedback from Gen 6 adopters without inventory issues is strong.

Risks and Challenges:

• Airway Clearance Timing: Inventory burn-off by DME partners is proceeding slower than forecasted, impacting Q3 results and Q4 guidance for this segment.
• Regulatory & Reimbursement: Dependency on CPT code approvals (Lymphatec) and payer policy changes for head and neck lymphedema; Category 3 codes do not guarantee immediate coverage decisions.
• Operational Friction: Ongoing need to improve conversion rates from referral to shipment due to documentation and order process complexities.
• Sales Force Annualization: Increased operating expenses in Q3 reflect the annualization of Salesforce hiring and continued technology investments.

Management Commentary and Tone:

• Tone was confident and optimistic regarding the durability of the lymphedema business and the effectiveness of strategic investments.
• Management emphasized "disciplined execution" balancing growth in core segments with operational efficiency improvements.
• CEO Sherry Dodd and CFO Elaine Berkemeyer expressed strong conviction that underlying market dynamics remain favorable and that inventory issues in airway clearance are temporary timing mismatches.
• Highlighted a shift from pure sales force expansion to a more sophisticated "go-to-market playbook" involving strategic accounts and AI-enabled order management.

Analyst Questions and Answers:

• 2027 Outlook: Analysts sought clarity on 2027 growth; management reiterated no specific guidance but expects durable growth, cautioning against expecting a "hockey stick" immediate spike from new product launches.
• Airway Clearance Normalization: Management confirmed the inventory transition will take longer than Q2 forecasts but expects sequential Q4 improvement and a return to "good business" dynamics once inventory clears.
• Margin Impact: FlexiTouch Pro will be priced as an EL652 with reimbursement matching current FlexiTouch codes, maintaining gross margins in the "zip code" of the current portfolio.
• Sales Force Strategy: Explained a plan to split territories as they grow, adding Territory Account Managers and Product Specialists, and the recent creation of a Strategic Accounts team for high-volume IDNs.
• Lymphatec Monetization: Confirmation that 3D scanner is currently monetized via SaaS at academic centers; final business model for Category 1 code monetization will be revealed in 2027.

Other Key Points:

• Strategic Priorities: Three pillars identified: (1) Expanding access to care via earlier diagnosis; (2) Creating value across the patient journey by reducing friction in the order process (AI-enabled review reduced medical record review time by 50%); (3) Expanding treatment options with new device launches.
• Marketing Efficiency: Clinician-focused marketing events generated 20–45% order growth in participating accounts within 90 days.
• Education: 13,000 clinicians educated on lymphedema treatment in 2026, a 25% increase over all of 2025.
• Capital Allocation: Continued commitment to investing in commercial/operational capabilities, disciplined M&A capacity, and share repurchases when valuation is attractive.